Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
Guido Kroemer, Oliver Kepp
Abstract
Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
Topics & Concepts
BlockadeMedicineImmunotherapyLung cancerImmune checkpointImmunogenic cell deathChemotherapyPD-L1Clinical trialOncologyT cellCancerImmune systemInternal medicineCancer researchImmunologyReceptorLung Cancer Research StudiesPeptidase Inhibition and AnalysisNeuroendocrine Tumor Research Advances